Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Reappraising the Approach to PV and ET

Curr Opin Hematol; ePub 2017 Nov 30; Vannucchi, et al

Description of recurrent genetic abnormalities in driver genes, a better appreciation of the key diagnostic role of bone marrow features, results of large epidemiologic studies, and landmark controlled clinical trials have resulted in a reappraisal of the approach to polycythemia vera and essential thrombocythemia, authors noted in a recent review.

The revised 2017 WHO classification of polycythemia vera and essential thrombocythemia allows early diagnosis and accurate distinction from other chronic myeloproliferative neoplasms, particularly prefibrotic myelofibrosis. The prognostic value of selected mutations is being investigated and JAK2V617F mutation is currently incorporated as risk variable in prognostic system for essential thrombocythemia. Risk-adjusted stratification is used to select therapeutic approaches that include target agents.


Vannucchi A, Guglielmelli P, Tefferi A. Polycythemia vera and essential thrombocythemia: Algorithmic approach. [Published online ahead of print November 30, 2017]. Curr Opin Hematol. doi:10.1097/MOH.0000000000000402.